Education
About Us
Working with TipRanks
Follow Us
Cannara Biotech (LOVFF)
OTHER OTC:LOVFF
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 28, 2025
|% Change Since: -7.92%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
Cannara Biotech demonstrated strong financial performance and market share growth, primarily driven by innovative product launches and operational efficiencies. However, they faced challenges in maintaining market share in certain provinces and managing cash flow. Overall, the positive achievements significantly outweigh the challenges.Company Guidance
Cannara Biotech's fiscal Q2 2025 earnings presentation highlighted the company's strong financial performance, marked by record high net revenues of CAD 26.6 million, representing a 6% increase quarter-over-quarter and a 35% increase year-over-year. The company reported a gross profit before fair value adjustments of CAD 10.8 million, achieving a gross margin of 41%. Adjusted EBITDA reached CAD 7.1 million, reflecting an 18% increase quarter-over-quarter and over 100% growth year-over-year, translating to a 27% adjusted EBITDA margin. Cannara's competitive advantages include its vertically integrated operations, cost-efficient cultivation, and premium product offerings, which have led to a 12.8% market share in Quebec and a 3.9% share nationally. With plans to expand cultivation capacity and introduce new products, Cannara aims to continue capturing market share while maintaining industry-leading margins.Record-Breaking Financial Performance
Cannara Biotech reported record revenue of CAD 26.6 million, up 6% quarter-over-quarter and 35% year-over-year. The company also achieved record gross profit of CAD 10.8 million and adjusted EBITDA of CAD 7.1 million, representing over 100% year-over-year growth.
Market Share Expansion
Cannara holds third market position in Quebec with a 12.8% market share, up over 40% from the prior year. Nationally, they are the seventh largest with a 3.9% market share, up from 2.9% the previous year.
Operational Efficiency and Growth
The company has increased its cultivation capacity by 20% with minimal capital expenditure and plans to further expand, aiming to produce up to 100,000 kilograms annually.
Innovative Product Launches
Cannara launched several new products, including the Tribal Trifecta infused pre-rolls and new genetic strains, contributing to their category leadership in infused pre-rolls and premium vapes.
---
LOVFF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LOVFF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 28, 2025 | $1.01 | $1.01 | 0.00% |
Jan 27, 2025 | $0.60 | $0.66 | +10.00% |
Nov 25, 2024 | $0.45 | $0.52 | +15.56% |
Jul 23, 2024 | $0.44 | $0.44 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cannara Biotech (LOVFF) report earnings?
Cannara Biotech (LOVFF) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Cannara Biotech (LOVFF) earnings time?
Cannara Biotech (LOVFF) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LOVFF EPS forecast?
Currently, no data Available
---